^
Association details:
| Biomarker: | LOX overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | paclitaxel (Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overexpression Of Lysil Oxidase Propeptide (LOX-PP) Results In Decreased Proliferation And Improved Chemosensitivity Of Ovarian Cancer Cells
Published date:
09/18/2023
Excerpt:
In vitro cytotoxicity assay demonstrated that LOX-PP overexpressing SKOV3 and A2780 cells were more sensitive to both cisplatin and paclitaxel. The A2780_ LOX-PP cells showed a 8,5% and 16% higher sensitivity to paclitaxel and cisplatin, respectively, while SKOV3¬_ LOX-PP cells showed 15% and 24% higher sensitivity to those drugs. Conclusion LOX-PP seems to exert an anti-cancer function in ovarian cancer, either by decreasing cells proliferation rate and/or by sensitizing of cells to chemotherapeutic agents.